Choroideremia Treatment Market Analysis

Route of Administration (Oral, Intravenous, Ophthalmic)

In choroideremia treatment market, ophthalmic segment is likely to account for around 40% share by 2036. The growth of this segment can be attributed on account of increasing integration of gene therapy in ophthalmic route of administration.

Gene therapy is regarded as a promising approach for treating choroideremia and its adoption is anticipated to rise in the upcoming years. This is owing to factors such as enhanced safety and efficacy profiles of gene therapy vectors and increasing clinical trial data supporting its effectiveness. Biogen Inc. initiated a Phase 3 STAR study of timrepigene emparvovec (BIIB111/AAV2-REP1), an investigational gene therapy for the potential treatment of choroideremia.

Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drugstores, Online Pharmacies)

In choroideremia treatment market, hospital pharmacies segment is predicted to hold more than 40% revenue share by 2036. Hospital pharmacies often serve as the central distribution point for specialized and high-cost medications such as those targeted for rare diseases like choroideremia.

This efficiency in supply chain management could benefit patients by ensuring timely access to treatment. Furthermore, as new choroideremia treatments especially gene therapy approaches reach the market, innovative reimbursement pathways are being explored. Hospital pharmacies are likely to play a crucial role in navigating these play a key role in navigating these reimbursement complexities and facilitating patient access to treatment.

Our in-depth analysis of the global choroideremia treatment market includes the following segments: